Latest Regulatory Progress News

Bio-Gene Technology Limited updates on its development of two novel insecticides, Flavocide and Qcide, highlighting regulatory progress, commercial partnerships, and a strong market outlook across multiple sectors.

Geopacific Resources has extended the Woodlark Gold Project Definitive Feasibility Study to Q1 2026, aiming to integrate optimisation and de-risking measures amid a gold price surge and promising drilling results.

Biotron Limited has launched a $1.5 million non-renounceable rights issue to fund its strategic acquisition of Sedarex Limited and support ongoing drug development programs. The capital raise follows shareholder approval and aims to diversify Biotron’s portfolio with a next-generation general anaesthetic.

Clover Corporation delivered a robust FY25 with strong second-half sales and operational milestones, positioning itself for continued growth in FY26 amid ongoing innovation and market expansion.

Island Pharmaceuticals has secured FDA confirmation that its antiviral Galidesivir can proceed under the Animal Rule pathway for Marburg virus, qualifying for a lucrative Priority Review Voucher. This regulatory milestone accelerates the drug’s path to approval and potential government stockpile inclusion.

Australian Bond Exchange narrowed its FY25 loss by 26% through disciplined cost cuts and is advancing its fintech strategy with AI-driven credit tools and tokenised asset ambitions.

Star Minerals has inked a pivotal Right to Mine Agreement with MEGA Resources and Bain Global Resources, unlocking $20 million in funding and operational support for its Tumblegum South Gold Project, aiming for production in early 2026.

DeSoto Resources has completed extensive drilling and sampling programs across its Guinea and Northern Territory projects, with assay results pending and new exploration permits approved to expand its footprint in the Siguiri Basin.

Memphasys Limited has successfully raised over $1.1 million through a pro-rata entitlement offer to accelerate the commercialisation of its innovative Felix™ sperm selection system, targeting key regulatory approvals and market expansion.

Westpac has agreed to sell its $21.4 billion RAMS mortgage portfolio to a consortium led by Pepper Money, KKR, and PIMCO, aiming to simplify operations and boost capital ratios despite an expected loss on sale.

Recce Pharmaceuticals has commenced patient dosing in its pivotal Phase 3 trial for diabetic foot infections in Indonesia, supported by promising antibacterial efficacy data and extended funding arrangements.

Key Petroleum Limited is on the cusp of securing critical government approvals for its Queensland projects, bolstered by new major shareholders and strategic board changes that set the stage for accelerated development and diversification.